A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to ...

Access the “What This Means” segment here LA JOLLA, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative ...

Pancreatic cancer has long been one of the most lethal diagnoses in medicine, largely because it spreads early and hides from ...

A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to ...

TOKYO & MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and ...

GRI Bio, Inc., a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, announced that the European Patent Office has ...

UCLA researchers have developed a new kind of immunotherapy that harnesses the body’s immune system to fight cancer more effectively. The innovative cell therapy uses specially engineered immune cells ...

GRI Bio, Inc., a biotechnology firm focused on developing treatments for inflammatory, fibrotic, and autoimmune diseases, announced that CEO Marc Hertz took part in a Virtual Investor CEO Connect ...

Immunotherapy. 2011;3(10):1167-1184. Specifically, iNKT cells appear to inhibit early disease progression with their loss facilitating disease progression, while at later inflammatory stages, NKT ...